Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate

Apr 23 2012

Related Content

Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End

Sep 15 2010

As Gout Market Opens Up, Experts Await Therapies To Better Lower Uric Acid

Nov 01 2009

Ardea's Phase III Program For Promising Gout Drug Begins To Take Shape

Jan 07 2011

Related Companies

AstraZeneca PLC

Ardea Biosciences, Inc.

Savient Pharmaceuticals, Inc.

Takeda Pharmaceutical Co. Ltd.

Bayer AG

Additional Topics

Europe United States Deals BioPharmaceutical

More from Europe

More from Geography

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window